Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy.
Therapy-related myelodysplastic syndrome (t-MDS) and acute nonlymphocytic leukemia (t-ANLL) are dramatic complications of cancer chemotherapy. Drugs like plant alkaloids or antimetabolites have not been reported to cause either t-MDS or t-ANLL. Monosomy 7(-7) and trisomy 8(+8) are among the most common abnormalities in myelodysplastic syndromes. Both abnormalities in two different clones of the same patient are very rarely reported. Such a myelodysplastic syndrome occurring shortly after treatment with an antimetabolite, the adenosine analogue cladribine (1-chlorodeoxadenosine), and involved field radiotherapy is reported here.
Laurencet
F M
FM
Division of Hematology, Geneva University Hospital, Switzerland.
Zulian
G B
GB
Cabrol
C
C
Betticher
D C
DC
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002897:Chromosomes, Human, Pair 7; D002898:Chromosomes, Human, Pair 8; D017338:Cladribine / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000235:genetics; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D014314:Trisomy
D000970:Antineoplastic Agents; D017338:Cladribine